SCHEMBL7044189

SCHEMBL7044189

O=CN(c1nc2cc(OS(=O)(=O)c3ccc(NCCO)cc3)ccc2[nH]1)C1CC1

nearest known ligand 0.33

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ENPP3 O14638 10/20 0.33
ENPP1 P22413 8/20 0.33
ENPP2 Q13822 7/20 0.33
ACE2 Q9BYF1 1/20 0.31
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA3 P07451 1/20 0.31
CA4 P22748 1/20 0.31
CA6 P23280 1/20 0.31
CA5A P35218 1/20 0.31
CA7 P43166 1/20 0.31
CA9 Q16790 1/20 0.31
CA14 Q9ULX7 1/20 0.31
ALDH1A1 P00352 2/20 0.31
KDM4E B2RXH2 1/20 0.31
ABL1 P00519 1/20 0.30
MAPT P10636 1/20 0.30
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6017806 0.96 ENPP3 (0.32) ENPP3ENPP1ENPP2ACE2
SCHEMBL6017766 0.94 ENPP3 (0.31) ENPP3ENPP1ENPP2
SCHEMBL6017898 0.93 KCNH3 (0.32) ENPP3ENPP1ENPP2
SCHEMBL6018120 0.89 ENPP3 (0.30) ENPP3ENPP1ENPP2
SCHEMBL5036606 0.89 ENPP3 (0.33) ENPP3ENPP1ENPP2CA12CA1
SCHEMBL6017660 0.88 ENPP3 (0.33) ENPP3ENPP1ENPP2ALDH1A1KDM4E
SCHEMBL6018066 0.87 ENPP3 (0.31) ENPP3ENPP1ENPP2ALDH1A1KDM4E
SCHEMBL6017897 0.86 ENPP3 (0.33) ENPP3ENPP1ENPP2ALDH1A1KDM4E
SCHEMBL5037949 0.86 CNR2 (0.33) ENPP3ENPP1ENPP2CA12CA1
SCHEMBL5141386 0.86 HTR6 (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1432417-A2 SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER Aventis Pharma S.A. (FR) 2004-06-30 EP disclosed
WO-2003028721-A2 SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER AVENTIS PHARMA S.A. (FR) 2003-04-10 WO disclosed